In terms of the interactions with patient organizations, the code specifies that companies should not only respect the autonomy of patient organizations and their independence, but also ensure that support for patient advocacy organizations in the form of grants or charitable contributions not be conditional on promoting a specific medicine.
This week, the Association for Accessible Medicines (AAM) released a new code of business ethics for its member companies. The new code will take effect on September 1, 2018.
“The AAM Code of Business Ethics stands out from other pharmaceutical industry codes because of AAM’s clear recognition of the ethical value of access to medicines for patients. Our new code also priorities market competition as a driving force,” said AAM president and CEO Chip Davis in a statement.
The code incorporates the following goals and criteria for its members:
In terms of the interactions with patient organizations, the code goes on to specify that companies should not only respect the autonomy of patient organizations, but also ensure that support for patient advocacy organizations in the form of grants or charitable contributions not be conditional on promoting a specific medicine.
The announcement of AAM’s new code comes on the heels of the recent launch of the new database, “Pre$cription for Power,” developed by Kaiser Health News (KHN). The database evaluated the 20 pharmaceutical companies, and logged 12,000 donations from the companies to patient advocacy groups in 2015. The data show that the pharmaceutical companies contributed at least $116 million to patient groups in 2015 alone. These data have caused some concern among stakeholders, who feel that the financial ties are troubling if they have caused a patient group to act in a way that does not represent the interest of its members.
AAM’s new code of business ethics addresses some of these concerns in regulations for its own members.
“We must never take the ethics of healthcare access for granted. Our companies believe in our ethical mission, and AAM’s Board of Directors has approved this code. AAM looks forward to working with all stakeholders to expand access to generic and biosimilar medicines—the proven, reliable way to drive down the cost of medicine, which helps patients, strengthens our economy, and benefits our society,” says the organization.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.